Skip to main content

New drugs in prostate cancer.

Publication ,  Journal Article
Armstrong, AJ; Carducci, MA
Published in: Curr Opin Urol
May 2006

PURPOSE OF REVIEW: The survival of hormone-refractory metastatic prostate cancer patients has improved with the use of docetaxel-based chemotherapy. The survival benefits, however, are modest suggesting that rationally designed therapeutic approaches are needed. We discuss recent developments in the therapeutic approach to advanced metastatic hormone-refractory prostate cancer, including molecularly targeted therapy, signal transduction inhibitors, stem-cell targeted therapy, anti-angiogenic compounds, vaccines and immunomodulating agents, differentiation agents, cytotoxics, and pro-apoptotic agents. RECENT FINDINGS: Over 200 compounds have entered clinical development for use in advanced prostate cancer, alone or in combination with cytotoxic agents such as docetaxel, or in other combinations. This article will review the results of emerging targets since the approval of docetaxel in 2004, concentrating on some of those compounds that, in our opinion, have the greatest potential and rationale for use. SUMMARY: The growing field of targeted molecular therapy of prostate cancer has opened up numerous opportunities for therapeutic impact. Knowledge of the molecular determinants of progression, relapse after local therapy, chemotherapeutic resistance, and hormone refractoriness remains essential in the rational design of clinical trials of these agents. Given the complexity, heterogeneity, and crosstalk of molecular pathways and the molecular lesions in prostate cancer, combination or sequential therapy may be a necessary step towards significant therapeutic progress. Novel translational clinical trial methodologies may assist in a more rapid identification of active compounds at biologically active doses for phase-III testing.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Curr Opin Urol

DOI

ISSN

0963-0643

Publication Date

May 2006

Volume

16

Issue

3

Start / End Page

138 / 145

Location

United States

Related Subject Headings

  • Urology & Nephrology
  • Signal Transduction
  • Prostatic Neoplasms
  • Male
  • Humans
  • Clinical Trials as Topic
  • Cancer Vaccines
  • Antineoplastic Agents, Hormonal
  • Antineoplastic Agents
  • Antibodies, Monoclonal
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Armstrong, A. J., & Carducci, M. A. (2006). New drugs in prostate cancer. Curr Opin Urol, 16(3), 138–145. https://doi.org/10.1097/01.mou.0000193390.69845.bb
Armstrong, Andrew J., and Michael A. Carducci. “New drugs in prostate cancer.Curr Opin Urol 16, no. 3 (May 2006): 138–45. https://doi.org/10.1097/01.mou.0000193390.69845.bb.
Armstrong AJ, Carducci MA. New drugs in prostate cancer. Curr Opin Urol. 2006 May;16(3):138–45.
Armstrong, Andrew J., and Michael A. Carducci. “New drugs in prostate cancer.Curr Opin Urol, vol. 16, no. 3, May 2006, pp. 138–45. Pubmed, doi:10.1097/01.mou.0000193390.69845.bb.
Armstrong AJ, Carducci MA. New drugs in prostate cancer. Curr Opin Urol. 2006 May;16(3):138–145.

Published In

Curr Opin Urol

DOI

ISSN

0963-0643

Publication Date

May 2006

Volume

16

Issue

3

Start / End Page

138 / 145

Location

United States

Related Subject Headings

  • Urology & Nephrology
  • Signal Transduction
  • Prostatic Neoplasms
  • Male
  • Humans
  • Clinical Trials as Topic
  • Cancer Vaccines
  • Antineoplastic Agents, Hormonal
  • Antineoplastic Agents
  • Antibodies, Monoclonal